https://scholars.lib.ntu.edu.tw/handle/123456789/551119
標題: | Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B | 作者: | Lin C.-L. CHEN-HUA LIU Wang C.-C. Liang C.-C. TUNG-HUNG SU CHUN-JEN LIU JIA-HORNG KAO |
公開日期: | 2015 | 出版社: | Lippincott Williams and Wilkins | 卷: | 49 | 期: | 8 | 起(迄)頁: | 705-713 | 來源出版物: | Journal of Clinical Gastroenterology | 摘要: | Goals/Background: Aspartate aminotransferase to platelet ratio index (APRI) and FIB-4 index are noninvasive biomarkers to evaluate hepatic fibrosis. However, their usefulness in chronic hepatitis B (CHB) patients remains unclear. Methods: A total of 631 CHB patients were enrolled and randomly divided into a training set (n=420) and a validation set (n=211). Areas under receiver operating characteristic (AUROC) curves for FIB-4 index and APRI were compared to evaluate their diagnostic values in identifying significant fibrosis and cirrhosis. Results: The AUROC of FIB-4 index for the diagnosis of significant fibrosis and cirrhosis in the entire cohort was higher than that of APRI (0.769 vs. 0.704, P=0.0003 and 0.869 vs. 0.706, P<0.0001). By using cutoff APRI of 0.38 and 4.04 in the validation set, the diagnostic accuracy for absence of significant fibrosis and presence of cirrhosis was 67.7% and 76.8%. At cutoff FIB-4 index of 0.87 and 3.40 in the validation set, the diagnostic accuracy for absence of significant fibrosis and presence of cirrhosis was 69.2% and 84.4%. Compared with patients with concordance, patients with overestimated score by FIB-4 index had a significantly higher serum alanine aminotransferase (ALT) level (299±245 vs. 168±196 U/L, P=0.001) as well as a higher ratio of hepatitis flare (ALT>400 U/L) (25% vs. 7.9%, P=0.008). Conclusions: FIB-4 index proves to be more reliable than APRI in predicting significant fibrosis and cirrhosis in CHB patients. By using FIB-4 index, a substantial proportion of patients could be identified correctly as significant fibrosis and cirrhosis without further invasive liver biopsy. Copyright ? 2015 Wolters Kluwer Health, Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942515740&doi=10.1097%2fMCG.0000000000000250&partnerID=40&md5=6f2fcca8edd5e4acbbf8133f5be65b17 https://scholars.lib.ntu.edu.tw/handle/123456789/551119 |
ISSN: | 0192-0790 | DOI: | 10.1097/MCG.0000000000000250 | SDG/關鍵字: | alanine aminotransferase; albumin; aspartate aminotransferase; bilirubin; hepatitis B(e) antigen; alanine aminotransferase; aspartate aminotransferase; biological marker; adolescent; adult; aged; alanine aminotransferase blood level; Article; aspartate aminotransferase to platelet ratio index; chronic hepatitis B; diagnostic accuracy; diagnostic test accuracy study; digestive system disease assessment; female; FIB 4 index; human; human tissue; liver biopsy; liver cirrhosis; liver fibrosis; major clinical study; male; priority journal; randomized controlled trial; thrombocyte count; very elderly; biopsy; blood; complication; controlled study; hepatitis B; liver cirrhosis; middle aged; procedures; retrospective study; validation study; virology; young adult; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Biopsy; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Retrospective Studies; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。